Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Diabetes Complications ; 10(4): 201-5, 1996.
Article in English | MEDLINE | ID: mdl-8835919

ABSTRACT

Because of the previous controversial findings in non-insulin-dependent diabetes mellitus (NIDDM), we measured bone-mineral density (BMD) by two different methods, studied biochemical markers of bone remodeling and calciotropic hormones (parathyroid hormone and calcitonin) in women with NIDDM, and compared the results with age-matched controls. Forty-seven women with NIDDM and 252 healthy nondiabetic women as controls were recruited for this study. BMD was measured by dual X-ray absorptiometry (DEXA) and by quantitative computed tomography (QCT). Biochemical markers of bone remodeling included plasma alkaline phosphatase (AP), osteocalcin (BGP), tartrate-resistant acid phosphatase (TRAP), parathyroid hormone (PTH), calcitonin (CT), and 24-h urine calcium, hydroxyproline. Diabetic patients were more obese with a higher body-mass index (BMI) than controls. Bone mass was normal in NIDDM, both by DEXA and by QCT. Biochemical markers of bone remodeling, PTH and CT were also normal. There was no statistical correlation between bone mass and any of the other measurements studied. There is no evidence that NIDDM produces any change in bone metabolism or mass.


Subject(s)
Bone Density , Bone and Bones/metabolism , Diabetes Mellitus, Type 2/metabolism , Absorptiometry, Photon , Acid Phosphatase/blood , Aged , Alkaline Phosphatase/blood , Biomarkers/blood , Biomarkers/urine , Blood Glucose/metabolism , Bone Remodeling/physiology , Calcification, Physiologic , Calcitonin/blood , Calcium/urine , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/urine , Female , Humans , Hydroxyproline/urine , Isoenzymes/blood , Kidney/physiopathology , Middle Aged , Osteocalcin/blood , Parathyroid Hormone/blood , Patient Compliance , Patient Selection , Surveys and Questionnaires , Tartrate-Resistant Acid Phosphatase , Tomography, X-Ray Computed
2.
J Clin Densitom ; 5(1): 27-34, 2002.
Article in English | MEDLINE | ID: mdl-11940726

ABSTRACT

The efficacy of alendronate in slowing the loss of bone mass, or even in increasing it, in osteoporotic patients and thus reducing the risk of new fractures has been described. Nevertheless, the way of taking this drug, together with its side effects, sometimes produces withdrawals. In this study, we analyzed if an alternative way of taking the alendronate improves the follow-up of the treatment and if it had the same effect on bone mineral metabolism than the traditional way of prescription. An open, intention-to-treat study, with follow-up of 2 yr was conducted. Eighty women suffering from postmenopausal osteoporosis were included in the study. They were classified in a random manner into two groups, each one of them received 10 mg/d alendronate, together with 1.2 g of calcium and 800 IU of Vitamin D3. Group I received the drug fasting, before breakfast, as usually prescribed and group II received the alendronate fasting, at noon, before lunch. Biochemical markers of bone remodeling were determined. Total alkaline phosphatase, osteocalcin, tartrate-resistant acid phosphatase, urine calcium/creatinine ratio, crosslinked N-telopeptides of type I collagen/creatinine ratio, serum calcium, and parathyroid hormone were also determined, and a lateral dorsolumbar radiography of the spine was performed. Bone mineral density was determined in the lumbar spine by dual-energy X-ray absorptiometry and quantitative computed tomography and by dual-energy X-ray absorptiometry in the proximal femur. Both groups showed an increase in bone mineral density in the lumbar spine and in the proximal femur, which was statistically significant after 1 yr of treatment in the range between 1.5% and 4.3%, depending on the anatomical localization where bone mineral density was measured. There was also an important decrease in the biochemical markers of bone remodeling, between 5.6% and 42.5%, depending on the biochemical marker; the decrease of amino-terminal telopetide during the first year was more important. The group that received alendronate in the morning reported a significantly higher number of withdrawals than the group that received the drug at noon. The alternative administration of 10 mg alendronate at noon had the same effect on bone mineral metabolism than its traditional administration in the morning, but the rate of withdrawals was significantly lower.


Subject(s)
Alendronate/administration & dosage , Bone Density/drug effects , Bone Remodeling/drug effects , Osteoporosis, Postmenopausal/drug therapy , Absorptiometry, Photon , Aged , Alendronate/therapeutic use , Female , Humans , Middle Aged
3.
Age Ageing ; 22(4): 285-8, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8213335

ABSTRACT

An epidemiological survey of proximal femoral fracture (PFF) was carried out in Gran Canaria (Canary Islands) in 1990. We identified 211 cases of PFF affecting residents, which gave an incidence of 161 per 100,000 per year (92 per 100,000 per year for men and 176 for women). Three quarters of all fractures occurred to residents of urban areas and nearly all fractures were caused by falls indoors. There was a higher incidence in winter than in summer months.


Subject(s)
Cross-Cultural Comparison , Hip Fractures/epidemiology , Africa, Western/epidemiology , Aged , Aged, 80 and over , Atlantic Islands/epidemiology , Costs and Cost Analysis , Cross-Sectional Studies , Female , Hip Fractures/economics , Humans , Incidence , Length of Stay/economics , Male , Middle Aged , Osteoporosis/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL